- OneSource Specialty Pharma’s partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®.
- OneSource acted as the CDMO partner, providing scale-up and manufacturing support from its US-FDA approved Bengaluru facility.
OneSource Specialty Pharma Limited announced that its partner Dr. Reddy’s Laboratories Ltd. has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. The approval enables commercialization of the product in Canada, with OneSource supporting the program as the contract development and manufacturing organization (CDMO) partner.
Under the collaboration, OneSource provides scale-up and contract manufacturing support for the semaglutide injection. The partnership is designed to ensure reliable and scalable commercial supply from the company’s US-FDA approved flagship manufacturing facility in Bengaluru.
The development reflects a coordinated effort between the two companies, combining Dr. Reddy’s expertise in peptide development with OneSource’s manufacturing capabilities. The product is a generic version of Ozempic®, a semaglutide-based therapy.
“We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”
Mr. Neeraj Sharma, CEO and Managing Director of OneSource Specialty Pharma Limited
